Ipamorelin
Also known as: Ipamorelin, IPA, NNC 26-0161, Ipa
Selective growth hormone releasing peptide — stimulates the body's own GH pulse without raising cortisol or prolactin, which distinguishes it from the older GHRPs.
Substance family
Growth hormone itself and the peptides that prompt the body to release it. Effects build over months rather than weeks, and reduced insulin sensitivity is what limits duration.
Effects on
Which outcomes this substance acts on — descriptive, not a recommendation.
Strain profile
Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.
This substance causes
Dosing & protocols by goal
Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.
Recovery and sleep
IntermediateDose
200–300 µg per administration
Frequency
2–3× daily, subcutaneous
Cycle length
8–12 weeks, then a break
One dose before bed is the most common single application, since the natural GH pulse occurs during deep sleep. Dose in µg, not mg.
Combination with a GHRH analogue
AdvancedDose
200–300 µg ipamorelin + 100 µg CJC-1295
Frequency
2–3× daily, subcutaneous
Cycle length
8–12 weeks, then a break
The standard pairing. The two act through different mechanisms and reinforce each other — GHRH raises the pulse, GHRP triggers it.
Higher doses
AdvancedDose
> 300 µg per administration
Frequency
Varies
Cycle length
—
The GH response saturates. Above roughly 300 µg the pituitary does not release proportionally more, so the additional amount is wasted.
Side effect & countermeasure
Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.
Problem
Water retention, tingling in the hands (carpal tunnel symptoms)
Countermeasure
A classic sign of too much GH activity. Reduce the dose rather than pushing through; symptoms usually resolve within days. If they persist, the dose was too high for too long.
Problem
Rising blood glucose and reduced insulin sensitivity
Countermeasure
Growth hormone works against insulin. Check fasting glucose and HbA1c for prolonged use; particularly relevant with pre-existing insulin resistanceinsulin resistanceHow strongly the body responds to its own insulin — worsened by growth hormone and by some blood-pressure drugs.. This is the effect that limits duration, not the peptidepeptideA short chain of amino acids — the reason this whole category has to be injected. itself.
Problem
Increased appetite through the ghrelin mechanism
Countermeasure
Ipamorelin acts on the ghrelin receptor, the body's hunger signal. Less pronounced than with older GHRPs but present — relevant in a diet phase, where it works against the goal.
Problem
Suppression of the body's own GH rhythm with continuous use
Countermeasure
Cycles of 8–12 weeks with genuine breaks rather than continuous use. The natural pulsatile rhythm is what the substance is meant to support, not replace.
Problem
Uncertain product quality on the grey market
Countermeasure
Only vendors with an independent HPLC/MS analysis certificate. Reconstitute with bacteriostatic water, store refrigerated, observe the shelf life after reconstitution.
Problem
Overestimating the effect relative to HGH
Countermeasure
A secretagogue raises the body's own release within physiological limits. It does not produce the levels that injected growth hormone does — expectations calibrated to HGH results will not be met.
Overview
Ipamorelin belongs to the growth hormone releasing peptides, a group of substances that prompt the pituitary to release the body's own growth hormone rather than supplying it from outside.
Its distinguishing feature is selectivity. The older peptides in this class — GHRP-2 and GHRP-6 — also raise cortisol and prolactin, which brings unwanted effects. Ipamorelin acts largely only on the intended pathway, which is the reason it has largely replaced them.
Mechanism of Action
The release of growth hormone is regulated by two opposing signals: GHRH stimulates it, somatostatin inhibits it. Ghrelin, the hormone better known for signalling hunger, acts on a third receptor and likewise triggers GH release.
Ipamorelin mimics ghrelin at this receptor. It triggers a GH pulse similar to the natural one — which is the essential difference from injected growth hormone. The body's own release remains pulsatile and stays within physiological regulation, including the feedback loops that prevent excess.
That is both the advantage and the limitation. Ipamorelin cannot produce the levels that exogenous HGH does, because the pituitary only releases what it has and only as much as its regulation permits. Anyone expecting HGH-level results will be disappointed; anyone looking for a gentler support of recovery and sleep will find the mechanism fits.
The two-hour half-life means the effect is short. This is why administration is split across the day, with one dose before bed — the natural GH pulse occurs during deep sleep, and the timing reinforces it.
Typical Context
Ipamorelin is used for recovery, sleep quality and, over longer periods, for connective tissue. Cycles run eight to twelve weeks with genuine breaks in between.
The standard pairing is with a GHRH analogue such as CJC-1295. The logic is mechanical: the two substances act on different receptors, and their combination produces a stronger pulse than either alone. GHRH raises the amount available for release, the GHRP triggers the release itself.
One limitation deserves attention because it defines duration. Growth hormone works against insulin, and prolonged elevation reduces insulin sensitivity. This is not specific to ipamorelin — it applies to anything that raises GH — but it is the reason cycles are limited rather than run continuously.
Side Effects & Risks
- Water retention, tingling in the hands, joint discomfort
- Rising blood glucose and reduced insulin sensitivity with prolonged use
- Increased appetite through the ghrelin mechanism
- Fatigue after administration, particularly at higher doses
- Local reactions at the injection site
- Suppression of the natural GH rhythm with continuous use
- Uncertain product quality on the grey market
Blood Work & Monitoring
- IGF-1 — the practical measure of GH activity; GH itself fluctuates too much to measure usefully
- Fasting glucose and HbA1c — the limiting factor for duration
- Thyroid values (TSH, fT3, fT4) — GH activity influences thyroid conversion
Harm-Reduction Notes
- Doses in µg, not mg — a factor-of-1000 error is the most common and most expensive mistake with peptides
- Above roughly 300 µg per administration the response saturates; more is wasted
- Cycle 8–12 weeks with genuine breaks rather than running continuously
- Water retention and tingling hands mean the dose is too high, not that it is working
- Check glucose for prolonged use; insulin sensitivity is the limiting factor
- Reconstitute with bacteriostatic water, store refrigerated, observe shelf life
- Only sources with an independent analysis certificate
Legal status by region
Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.
| Region | Regulatory status |
|---|---|
| United States | Not approved for human useSold as a research chemical; marketing for human consumption is unlawful. |
| EU / UK | No marketing authorisationNeither a medicine nor a supplement — no legal route for human use. |
| Most other jurisdictions | Unregulated grey areaPossession is legal in many places precisely because no framework covers it. That is not an indication of safety. |
| Competitive sport | ProhibitedListed by WADA where a relevant class applies. |